Study of Natural Products Adverse Reactions (SONAR) in Adults with Mental Health Conditions: A Cross-Sectional Study

Liliane Zorzela, Baljit Khamba, Emma Sparks, Candace Necyk, Liana Urichuk, Martin A. Katzman, David Koczerginski, Pierre Chue, Joanne Barnes and Sunita Vohra ()
Additional contact information
Liliane Zorzela: University of Alberta
Baljit Khamba: Bastyr University California-San Diego Campus
Emma Sparks: University of Toronto
Candace Necyk: University of Alberta
Liana Urichuk: University of Alberta
Martin A. Katzman: Northern School of Medicine (NOSM)
David Koczerginski: University of Toronto
Pierre Chue: University of Alberta
Joanne Barnes: University of Auckland
Sunita Vohra: University of Alberta

Drug Safety, 2021, vol. 44, issue 9, No 8, 999-1006

Abstract: Abstract Introduction Mental illness is a leading cause of non-fatal disease burden worldwide. Natural health products (NHPs) are sought by patients with mental health conditions as a safer and more ‘natural’ option than conventional pharmacotherapy; however, the possible adverse events (AE) and interactions between NHPs and prescription medicines are not fully known. Objectives The aim of this study was to determine (i) the prevalence of adult patients with mental health conditions taking prescription medications only, NHPs only, NHPs and prescription medications concurrently, or neither, (ii) which prescription medications and NHPs are most commonly used, (iii) AEs (serious and non-serious) experienced in the last 30 days for each product use group. Methods Mental health clinics in Alberta and Ontario, Canada, were included in an active surveillance study investigating NHP–drug interactions. On their first clinic visit, adult mental health patients were provided with a form inquiring about prescription drug use, NHP use, and any undesirable health events experienced in the last month. Healthcare professionals were also asked to report AEs. Results A total of 3079 patients were screened at 11 mental health clinics in Alberta and Ontario. In total, 620 AEs were reported in 447 patients (14.9%). The majority of adverse events were seen in patients using both NHPs and prescription medicines (58.8%), followed by patients taking only prescription medicines (37.1%), NHPs only (3.4%) and neither (0.67%). Combining NHPs and prescription medications increases the likelihood of experiencing AEs (OR 2.1; p

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-021-01092-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:44:y:2021:i:9:d:10.1007_s40264-021-01092-w

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-021-01092-w

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().